Dehydrolithocholic Acid

Your gut bacteria are constantly reworking the bile acids your liver makes, turning a small set of starting molecules into dozens of chemically distinct cousins. Dehydrolithocholic acid is one of those reworked forms, and it sits in a family of molecules that researchers are increasingly linking to liver health, kidney function, and the gut-brain conversation.

This is a research-grade stool measurement, not a settled clinical test. There are no agreed-upon cutpoints and no guideline that tells a doctor what to do at a given level. What this test offers is an early window into a piece of your gut biology that standard panels do not capture, which is most useful when you track it over time and read it alongside the rest of your bile acid profile.

Where Dehydrolithocholic Acid Comes From

DHLCA (dehydrolithocholic acid) is a secondary bile acid, meaning your liver does not make it directly. Your liver makes a small set of primary bile acids and releases them into your gut to help digest fat. Once they reach the lower intestine, certain bacteria chemically modify them. Lithocholic acid is one of those bacterial products, and dehydrolithocholic acid is an oxidized variant of lithocholic acid produced by further microbial activity. In the recent literature, DHLCA is most often identified as 3-keto-lithocholic acid (also written as 3-oxoLCA), the form produced when bacterial enzymes oxidize the 3-hydroxyl group of lithocholic acid. The general term can refer to other keto-LCA isomers depending on which hydroxyl group is oxidized.

Because the molecule depends on specific microbial steps, its level in stool reflects two things at once: how much bile acid your liver is sending downstream, and which microbes are present in your gut to perform the necessary conversions. When research describes the broader pool of secondary bile acids as reduced, it often means those bacterial conversion steps are not happening at a normal pace.

Diabetic Kidney Disease

The clearest human signal for this specific molecule comes from work in diabetic kidney disease. In a study of people with type 2 diabetes and varying degrees of kidney involvement, plasma DHLCA was one of several bile acids that differed across healthy controls, type 2 diabetes, and diabetic kidney disease at different albuminuria stages. Levels were significantly lower in people with the most advanced kidney involvement (macroalbuminuria) than in those with diabetes alone or with milder kidney involvement.

After adjusting for age and how long someone had diabetes, DHLCA showed a negative correlation with urine albumin and the urine albumin-to-creatinine ratio. In plain terms, the worse the kidney leak of protein, the lower the DHLCA. That study measured plasma, not stool, so this finding tells you the molecule tracks with kidney disease severity in the bloodstream. Whether the stool measurement moves in step has not been directly studied.

Fatty Liver Disease

In pediatric nonalcoholic fatty liver disease, the overall pool of fecal secondary bile acids, including lithocholic acid, is reduced compared with healthy children. The drop tracks with shifts in the gut microbes that perform bile acid conversion, particularly losses of bacteria from the Eubacterium and Ruminococcaceae groups. Several oxidized derivatives of lithocholic acid (such as 12-ketolithocholic acid, 7,12-diketolithocholic acid, and alpha-hyodeoxycholic acid) are also reported as reduced in related liver disease studies, though the pediatric NAFLD work focused on the overall secondary bile acid drop rather than a definitive list of these specific molecules.

The pattern is not uniform across the spectrum of fatty liver disease. In adult nonalcoholic fatty liver disease with fibrosis, serum dehydroLCA has been reported as increased with rising fibrosis stage, the opposite direction from what is seen in pediatric NAFLD overall. The takeaway is that DHLCA-related bile acids can move in either direction in liver disease depending on disease stage, severity, and whether the measurement is taken in stool, serum, or plasma. No published study has isolated DHLCA in stool as a specific liver disease marker.

Cognitive Health and the Gut-Brain Axis

A pilot study of cerebrospinal fluid in people with Alzheimer's disease, mild cognitive impairment, and unaffected controls found that dehydrolithocholic acid (identified in that work as 3-keto-LCA) was statistically higher in the Alzheimer's group than in either of the comparison groups. The molecule had not previously been reported in cerebrospinal fluid, and the researchers framed it as an exploratory finding tied to the gut-brain axis rather than a diagnostic marker.

That finding does not translate directly to what a stool measurement means. Bile acids in cerebrospinal fluid reach the brain through a different route than those that stay in the gut. The point worth taking away is that this molecule is being investigated in conditions ranging from kidney disease to neurodegeneration, which is why it has earned a place in research-oriented stool panels.

Resolving the Conflicting Direction Across Diseases

The literature shows DHLCA moving in different directions across diseases, disease stages, and body compartments. It is lower in plasma in advanced diabetic kidney disease, lower in stool as part of the broader secondary bile acid drop in pediatric fatty liver disease, but higher in serum with rising fibrosis stage in adult NAFLD and higher in cerebrospinal fluid in Alzheimer's. This is not a contradiction. DHLCA is not a simple good-or-bad number. It is a marker of bacterial bile acid processing, and the right direction depends on the disease, the stage, and the body compartment being measured. The most useful way to read a stool DHLCA result is in the context of your full bile acid profile, not as a single number to push higher or lower.

Why One Reading Is Not Enough

Bile acid output in stool is shaped by what you ate in the days before the sample, the timing of bowel movements, the makeup of your microbiome that week, and the speed at which food moves through your gut. No clinical biological variability data exists for DHLCA specifically, but most stool bile acid measurements show meaningful day-to-day swings. A single reading is hard to act on in isolation.

Trend matters more than any one number. A reasonable approach is to establish a baseline, retest in 3 to 6 months if you are changing your diet, adding fiber, taking a course of antibiotics, or starting a probiotic regimen, and then at least once a year after that. What you are looking for is a stable pattern in the context of how the rest of your bile acid profile is moving, not a one-time value to chase.

When Results Can Be Misleading

• Recent antibiotic use: antibiotics that wipe out anaerobic gut bacteria can sharply reduce the production of all secondary bile acids, including DHLCA, for days to weeks after the course ends, with the exact recovery time depending on the antibiotic class and the individual. A reading taken in that window can look alarmingly low without indicating any underlying disease.
• Diet in the days before sampling: high-fat meals increase bile acid release into the gut, while very low-fat or low-calorie patterns reduce it. Either can shift a single measurement.
• Sample handling: stool bile acids degrade with prolonged warm exposure. Following the kit's freezing and shipping instructions matters more for this kind of test than for routine blood work.
• Active gut infection or flare: acute diarrhea, an inflammatory bowel flare, or a recent gastrointestinal illness can dramatically alter what your microbes are doing and what ends up in stool.

What to Do With an Out-of-Pattern Result

Because this is a research marker without standardized cutpoints, the response to an unusual reading is rarely about the DHLCA value alone. Look at the rest of the bile acid panel. If primary bile acids are high and most secondary bile acids (including DHLCA) are low, that points toward impaired microbial conversion. If the whole bile acid pool is suppressed, recent antibiotics, severe dietary restriction, or a gut motility issue is worth considering.

Combinations matter more than single values. A pattern of low DHLCA alongside other low oxidized lithocholic derivatives and reduced bacterial diversity on a microbiome test gives you a clearer story than DHLCA on its own. If your reading sits well outside what is reported in healthy populations and you have a related condition (kidney disease, fatty liver, persistent gut symptoms), that is the moment to bring the result to a gastroenterologist or a physician comfortable interpreting bile acid panels rather than to act on the number yourself.